• By ICR Secretariat
  • Posted Thursday, October 13, 2022

OPTIMA announce AstraZeneca and Mutabor as official partners

https://www.pharmatimes.com/news/optima_announce_astrazeneca_and_mutabor_as_official_partners_1456507

The companies will aim to improve treatment for patients with prostate, breast and lung cancer

The Innovative Medicines Initiative (IMI) – a joint undertaking of the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) – has announced the launch of the public-private research programme OPTIMA (Optimal Treatment for Patients with Solid Tumours in Europe Through Artificial intelligence).